Company intelligence / Profile preview

PepTx

Minnesota, United States

Ownership: Private
Development stage: Other

Overview

As of early 2025, PepTx has five peptide drug candidates in preclinical or pending stages, one of which targets galectin-1 in cancer; no clinical-stage or approved products yet.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Peptides
Industry: Biotech

Partnerships

Originator institution for some drugs is University of Minnesota

Beyond the preview

Go deeper on PepTx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PepTx.

Explore the full profile